

# CITATION REPORT

List of articles citing

## Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer

DOI: 10.1007/s11523-019-00646-4  
Targeted Oncology, 2019, 14, 307-314.

**Source:** <https://exaly.com/paper-pdf/73135618/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
4	Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study. <i>PLoS ONE</i> , <b>2019</b> , 14, e0221575	3.7	7
3	Real-world data on treatment outcomes in -mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines. <i>Future Oncology</i> , <b>2021</b> , 17, 2513-2527	3.6	0
2	Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/French-Language Oncology Group (GOLF).. <i>Cancers</i> , <b>2022</b> , 14,	6.6	0
1	Identifying octogenarians with non-small cell lung cancer who could benefit from surgery: A population-based predictive model. <i>Frontiers in Surgery</i> , 9,	2.3	